Imagabalin
Chemical compound
From Wikipedia, the free encyclopedia
Imagabalin (INN, USAN; PD-0332334) was an investigational drug that acts as a ligand for the α2δ subunit of the voltage-dependent calcium channel,[1] with some selectivity for the α2δ1 subunit over α2δ2.[2] It was under development by Pfizer as a pharmaceutical medication due to its hypothesized anxiolytic, analgesic, hypnotic, and anticonvulsant-like activity. It reached phase-III clinical trials for treatment of generalized anxiety disorder; however, the trials were terminated by the manufacturer.[3][4][5][6] The drug is no longer under development.
 | |
| Clinical data | |
|---|---|
| Other names | PD-0332334; PD-332,334 |
| ATC code |
|
| Identifiers | |
| |
| CAS Number |
|
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C9H19NO2 |
| Molar mass | 173.256 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Synthesis
Protein engineering has been used to modify the Vibrio fluvialis aminotransferase to catalyze the asymmetric transamination of a synthetic intermediate.[7]
